Man Group
ANIK icon

Man Group’s Anika Therapeutics ANIK Stock Holding History

Man Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Buy
140,712
+16,419
+13% +$243K ﹤0.01% 1556
2026
Q1 		$1.8M Buy
124,293
+60,015
+93% +$697K ﹤0.01% 1614
2025
Q4 		$618K Buy
64,278
+49,500
+335% +$474K ﹤0.01% 1834
2025
Q3 		$139K Buy
14,778
+1,510
+11% +$14.4K ﹤0.01% 2137
2025
Q2 		$140K Buy
+13,268
New +$167K ﹤0.01% 2106
2024
Q1 		– Sell
-29,700
Closed -$673K – 2109
2023
Q4 		$673K Buy
+29,700
New +$615K ﹤0.01% 1573
2023
Q3 		– Sell
-25,700
Closed -$533K – 1512
2023
Q2 		$668K Buy
+25,700
New +$688K ﹤0.01% 1501
2023
Q1 		– Sell
-12,000
Closed -$357K – 1652
2022
Q4 		$355K Buy
+12,000
New +$341K ﹤0.01% 1600
2018
Q4 		– Sell
-31,621
Closed -$1.33M – 1904
2018
Q3 		$1.33M Sell
31,621
-6,195
-16% -$245K ﹤0.01% 1558
2018
Q2 		$1.21M Buy
37,816
+26,803
+243% +$1.1M 0.01% 1548
2018
Q1 		$548K Buy
+11,013
New +$622K ﹤0.01% 1691

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Man Group's ANIK Position: Q2 2026 in Review

Man Group increased its Anika Therapeutics (ANIK) stake by 13% in Q2 2026, buying an estimated $243K and bringing the position to 140,712 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

Man Group first reported a position in ANIK in Q1 2018 and has held it in 11 quarters since. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Man Group held 140,712 shares of Anika Therapeutics worth $2.06M as of Q2 2026.
  • Man Group bought 16,419 Anika Therapeutics shares in Q2 2026, an estimated $243K.
  • Anika Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1556 holding.
  • Man Group first reported a position in Anika Therapeutics in Q1 2018 and has held it in 11 quarters since.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.